middle.news
Botanix Reports 487% Revenue Growth as Sofdra Gains US Market Traction
5:53pm on Wednesday 26th of August, 2026 AEST
•
Healthcare
Read Story
Botanix Reports 487% Revenue Growth as Sofdra Gains US Market Traction
5:53pm on Wednesday 26th of August, 2026 AEST
Key Points
487% revenue increase to $33.8 million
Net loss narrowed 19.25% to $69.8 million
Sofdra prescriptions shipped grew 527% to 105,794
Sales force realignment to cut costs by ~12%
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Botanix Pharmaceuticals (ASX:BOT)
OPEN ARTICLE